This week: Restriction of monoclonal antibodies recommended due to Omicron; Veklury given the go-ahead as an outpatient treatment; NDA for parsaclisib withdrawn; new data produces a reconsideration for Pepaxto withdrawal; and a new treatment approved for unresectable or metastatic uveal melanoma.